Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

OBJECTIVE: To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-M...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109953/
https://www.ncbi.nlm.nih.gov/pubmed/27733571
http://dx.doi.org/10.1212/WNL.0000000000003319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109953/
https://www.ncbi.nlm.nih.gov/pubmed/27733571
http://dx.doi.org/10.1212/WNL.0000000000003319

Ejemplares similares